Clarification Sought from Sun Pharmaceutical Industries Ltd
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 29, 2018 with reference to news appeared in "The Economic Times" dated November 29, 2018 quoting "Governance cloud over Sun Pharma"The reply is awaited. Sun Pharma hits 5-month low; stock slips 7%
The stock dipped 7% to Rs 475, its lowest level since June 6, 2018 on the BSE. Intimation Of Settlement In The In Re Modafinil Antitrust Litigation Matter In US With Certain Plaintiffs
Please note that Sun Pharmaceutical Industries Ltd. and one of its wholly-owned subsidiaries have entered into settlements with certain plaintiffs in the In re Modafinil Antitrust Litigation matter pending in the United States District Court for the Eastern District of Pennsylvania. The settlements extend to all claims brought by the Direct are confidential. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Sudhir Valia Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to acquisition of Pola Pharma Inc., Japan, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Announcement under Regulation 30 (LODR)-Acquisition
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the revised disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd Growth concerns resurface for Sun Pharma after disappointing second quarter
Analysts cut earnings estimates on muted India business growth outlook, rising expenses on specialty launches in the US